Objective:

To evaluate the efficacy and safety of CG-P5 eye drop therapy as a noninvasive alternative to intravitreal injections for neovascular age-related macular degeneration (nAMD).

Approach:

Key Findings:

• CG-P5producedastatisticallysignificantreductioninCSTcomparedtoplaceboatday56.MagnitudeofCSTreductionwithCG-P5wascomparabletothatofaflibercept.CG-P5achievedan83%intraretinalfluidclearancerateatday56,comparedto60%forafliberceptand25%forplacebo.CG-P5resultedinapproximately78%reductionindiseaseactivitybyday84,comparedto57%intheafliberceptarm.CG-P5waswelltoleratedwithnosevereadverseeventsreported.Approximately20%ofpatientsinthetreatmentgroupexperiencedmild,temporarystudyeyeirritation,whichresolvedquickly.

Interpretation:

The study indicates that CG-P5 may provide a reduction in retinal thickness and disease activity, comparable to standard treatments.

Limitations:

• Thestudyislimitedbyitssmallsamplesizeandshortduration.Largerstudiesareneededtoconfirmefficacyanddurability.

Conclusion:

CG-P5 has the potential to become the first noninvasive topical therapy for treatment of neovascular AMD.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.